Ashfield and Sharp Packaging Services, both part of UDG Healthcare, a global leader in providing outsourced healthcare services to pharmaceutical, device and biotech companies, have announced that Diurnal Group plc (Diurnal), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, has selected Ashfield to support Diurnal in building sales and medical infrastructure in major European territories and Sharp to provide services related to the commercial supply of Infacort.
Ashfield provides sales teams, healthcare communications, strategic consulting, in-home and call centre nurse educators, medical information, pharmacovigilance (drug safety) and event management services to more than 300 healthcare companies with offices in 22 countries, including the United Kingdom, America, Germany, Spain and Japan.
Sharp Packaging Services is a leader in contract packaging and clinical trial supply services to the pharmaceutical and biotechnology industries. Operating from nine state-of-the-art facilities across the United States and Europe, Sharp offers services in the fields of commercial packaging, clinical services, packaging and label design, IRT and serialisation solutions.
Mark Gibson, Director of International Business at Ashfield, said: “We are delighted to be working with Diurnal on launching their products across key European markets. We will be able to support Diurnal in successfully launching treatments for chronic endocrine diseases and ultimately be able to make a difference to the lives of these patients. Diurnal have fantastic products in their pipeline and we are looking forward to working with them.”
Dr Martin Whitaker, CEO of Diurnal, commented: “Following the submission of our regulatory application to the EMA for Infacort and its subsequent validation, we are focused on prelaunch activities for this product in Europe. We are confident that the agreements with Ashfield and Sharp, both leading providers of outsourced commercialisation services to the pharmaceutical industry, will help ensure the prompt and effective market introduction of Infacort® following its anticipated approval in Europe.”